Table 1.
Isothiocyanates differently affect cell-cycle progression in fibroblasts and prostate cancer cells
| Hours (h) | Cells | DMSO | SFN | PEITC | Etop |
|---|---|---|---|---|---|
| 6 | HDFa | ||||
| G0/G1 | 83.0 ± 2.2 | 81.9 ± 1.9 | 81.3 ± 2.0 | ||
| S | 5.2 ± 1.0 | 8.1 ± 2.2 | 11.1 ± 2.9 | ||
| G2/M | 11.8 ± 1,3 | 10.0 ± 1.5 | 7.6 ± 2.1 | ||
| 6 | PC-3 | ||||
| G0/G1 | 53.5 ± 3.1 | 49.8 ± 3.7 | 48.4 ± 3.7 | ||
| S | 12.5 ± 0.6 | 16.2 ± 3.6 | 16.1 ± 3.5 | ||
| G2/M | 34.0 ± 3.6 | 34.0 ± 4.4 | 35.5 ± 4.3 | ||
| 16 | HDFa | ||||
| G0/G1 | 83.0 ± 1.9 | 78.2 ± 0.7 | 75.2 ± 0.7 | ||
| S | 5.4 ± 1.4 | 10.6 ± 1.6 | 14.8 ± 2.1* | ||
| G2/M | 11.6 ± 2.6 | 11.2 ± 2.1 | 10.0 ± 2.7 | ||
| 16 | PC-3 | ||||
| G0/G1 | 58.9 ± 6.9 | 51.0 ± 2.2 | 51.1 ± 2.8 | ||
| S | 11.5 ± 0.6 | 14.2 ± 1.1 | 11.0 ± 0.8 | ||
| G2/M | 29.6 ± 6.4 | 34.8 ± 2.5 | 37.9 ± 1.9 | ||
| 24 | HDFa | ||||
| G0/G1 | 81.2 ± 2.0 | 84.2 ± 1.4 | 79.6 ± 2.8 | 81.6 ± 1.2 | |
| S | 7.8 ± 3.6 | 8.6 ± 2.6 | 8.9 ± 1.2 | 8.7 ± 1.9 | |
| G2/M | 11.0 ± 2.5 | 7.2 ± 1.9 | 11.5 ± 3.7 | 9.7 ± 1.1 | |
| 24 | PC-3 | ||||
| G0/G1 | 58.3 ± 4.0 | 53.1 ± 2.8 | 50.0 ± 3.1 | 27.1 ± 5.6*** | |
| S | 14.6 ± 2.9 | 14.4 ± 2.1 | 14.6 ± 2.1 | 28.5 ± 1.4** | |
| G2/M | 27.1 ± 4.0 | 32.5 ± 5.0 | 35.4 ± 4.6 | 44.4 ± 4.2* | |
Human dermal fibroblasts (HDFa) and prostate cancer cells (PC-3) were treated for indicated time with DMSO (control), 40 µM SFN, 10 µM PEITC or 20 µM etoposide (Etop; positive control). The results are expressed as the mean ± SE of 3 independent experiments
Statistical significance of differences between means was tested by Bonferroni’s multiple comparison test (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between DMSO and SFN or PEITC)